Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RPI-78
- Development stage
- Discontinued
- Lead developer
- Nutra Pharma
- Modality
- Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
RPI-78 is a catalytic RNA molecule, specifically a hammerhead ribozyme, designed to target and cleave the messenger RNA (mRNA) encoding Tumor Necrosis Factor-alpha (TNF-alpha). Developed by Ribozyme Pharmaceuticals, the drug was intended to treat inflammatory diseases, most notably rheumatoid arthritis, by preventing the synthesis of the TNF-alpha protein at the pre-translational level. This approach aimed to offer a more precise method of cytokine inhibition compared to traditional protein-based therapies like monoclonal antibodies. Clinical development reached Phase 1/2 trials in the late 1990s, but the program was ultimately discontinued as the company shifted its focus toward RNA interference (RNAi) technologies and was later acquired by Merck & Co.
- Other names
- TNF-alpha ribozyme
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on RPI-78.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RPI-78.